Management

• • Primary prevention: statin if QRISK3 ≥10% — atorvastatin 20 mg
• • Secondary prevention: atorvastatin 80 mg (or rosuvastatin 20-40 mg)
• • Target: LDL <1.8 mmol/L or ≥50% reduction (secondary); LDL <1.4 if very high risk (ESC 2019)
• • Add ezetimibe 10 mg if not at goal
• • PCSK9i (evolocumab/alirocumab) if still not at goal or intolerant